

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING OPERATION

Applicant(s): David FAIRLIE et al.

Serial No. 10/596,074

Group Art Unit: 1625

Filed: May 26, 2006

Examiner:

Att. Docket No.: P1119/20002

Confirmation No.: 1505

For: ANTI-CANCER AGENTS

**SUPPLEMENTAL PRELIMINARY AMENDMENT IN RESPONSE TO  
NOTIFICATION TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INTRODUCTORY COMMENTS**

Supplemental to the May 26, 2006 Preliminary Amendment, and in response to the April 4, 2007 NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES, please further amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.

A written version of the Sequence Listing is attached following page 3.